Tag Archives: ProNAi Therapeutics

March, 2016

  • 14 March

    ProNAi’s DLBCL Candidate Awarded FDA Orphan Drug Designation

    VANCOUVER, March 14, 2016 /PRNewswire/ – ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company advancing novel therapeutics for patients with cancer and hematological diseases, today announced that its oncology drug candidate PNT2258 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of diffuse …